Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Equity Average (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Equity Average readings, the most recent being $15.5 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 380.54% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.5 million, a 380.54% increase, with the full-year FY2025 number at $14.8 million, up 269.2% from a year prior.
  • Equity Average hit $15.5 million in Q4 2025 for Fennec Pharmaceuticals, up from -$6.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $27.0 million in Q1 2021 to a low of -$11.1 million in Q4 2023.
  • Median Equity Average over the past 5 years was -$1.6 million (2022), compared with a mean of $3.5 million.
  • Biggest five-year swings in Equity Average: crashed 9607.73% in 2023 and later soared 380.54% in 2025.
  • Fennec Pharmaceuticals' Equity Average stood at $17.4 million in 2021, then crashed by 99.33% to $116500.0 in 2022, then crashed by 9607.73% to -$11.1 million in 2023, then skyrocketed by 50.15% to -$5.5 million in 2024, then soared by 380.54% to $15.5 million in 2025.
  • The last three reported values for Equity Average were $15.5 million (Q4 2025), -$6.0 million (Q3 2025), and -$6.7 million (Q2 2025) per Business Quant data.